

Fusion Pharmaceuticals To Participate At The Cowen 42nd Annual Health Care Conference

HAMILTON, ON and BOSTON, Feb. 28, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in the "Novel Oncology Targets" panel at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022, at 12:50 p.m. ET. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.

A webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at <https://ir.fusionpharma.com/events-webcasts>. A replay of the webcast will be archived on the Company's website for approximately 30 days following the panel discussion.

About Fusion

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434 targeting insulin-like growth factor 1 receptor, is currently in a Phase 1 clinical trial. The pipeline includes FPI-1966, targeting the fibroblast growth factor receptor 3 (FGFR3), advancing to a Phase 1 study following the recent investigational new drug (IND) clearance; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1). In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Repair Inhibitors (DDRIs) and immuno-oncology agents. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. Fusion and Hamilton, Ontario-based McMaster University are building a current Good Manufacturing Practice (GMP) compliant radiopharmaceutical manufacturing facility designed to support manufacturing of the Company's growing pipeline of TATs.

Fusion Contact: Amanda Cray, Senior Director of Investor Relations & Corporate Communications, 617-967-0207, cray@fusionpharma.com

SOURCE Fusion Pharmaceuticals Inc.

<https://ir.fusionpharma.com/2022-02-28-Fusion-Pharmaceuticals-to-Participate-at-the-Cowen-42nd-Annual-Health-Care-Conference>